巴曲酶合用丹参川芎嗪治疗急性脑梗死疗效观察

Clinical Study on the Effect of Salviae Miltiorrhizae and Ligustrazine for Injection Combined with Batroxobin on Acute Cerebral Infarction

目的:观察巴曲酶联合丹参川芎嗪治疗急性脑梗死的临床疗效。方法:选择收治的急性脑梗死患者100例作为研究对象,随机分为观察组(巴曲酶+丹参川芎嗪)50例和对照组(巴曲酶)50例,比较两组的临床疗效和神经缺失功能评分。结果:两组治疗2周后,观察组的显效率明显高于对照组,差异有统计学意义(P<0.05)。治疗7 d后,两组的神经功能缺损评分较治疗前均明显降低,且观察明显低于对照组,较对照组改善明显(P<0.05)。治疗14 d后,观察组的神经功能缺损评分改善更为显著(P<0.01)。结论:巴曲酶联合丹参川芎嗪较单用巴曲酶疗效更明显,显效率高,且能有效降低患者的神经功能缺损评分,值得推广。

Objective：To investigate the efficacy and safety of Salviae Miltiorrhizae and Ligustrazine for Injection combined with batroxobin（DF-521） for acute cerebral infarction. Methods：One hundred patients with acute cerebral infarction were randomly divided into 2 groups.Therapy group（50 cases） were given Salviae Miltiorrhizae and Ligustrazine for Injection combined with batroxobin.Control group（50 cases） were given batroxobin.The effect were evaluated by index of NIHSS before therapy and 7days、14 days after treatment,respectively.At the same time inspected the side-effect. Results：There were significant differences between the two groups on index of NIHSS.The total efficiency rate were 82% and 70%,respectively（P0.05）. Conclusions：Salviae Miltiorrhizae and Ligustrazine for Injection combined with batroxobin is effective and safe on acute cerebral infarction.